Small N L, Giamonna K A
Department of Pharmacy, Central Texas Veterans Healthcare System, Temple 76504, USA.
Ann Pharmacother. 2000 Jun;34(6):734-6. doi: 10.1345/aph.19336.
It is well known that there are many drug interactions involving warfarin. However, few data have been supplied to guide clinicians concerning the interaction between trazodone and warfarin.
Three clinically significant cases of suspected trazodone and warfarin interactions were identified in a retrospective chart review based on changes in the prothrombin time (PT) and international normalized ratio (INR) that were not explained by other factors. In each of the cases, the INR changed by > or = 1.0 after the initiation or discontinuation of trazodone. In the patients who started trazodone, a subsequent decrease in the PT and INR resulted; conversely, the PT and INR increased in the patient who stopped trazodone therapy. Although none of the patients experienced adverse effects due to the marked changes in PT and INR, the warfarin dosages had to be adjusted accordingly on initiation and discontinuation of trazodone.
These cases show that there is a potentially clinically significant interaction between trazodone and warfarin. The time to onset of the interaction is variable; the mechanism behind it is not known, but it may involve substrate or protein-binding competition.
The use of trazodone on an as-needed basis for sleep is strongly discouraged in patients who are receiving warfarin, due to the difficulty of achieving a therapeutic PT and INR. Until more is known, patients and clinicians should be educated about this potential interaction and monitor for changes in the anticoagulant effects when trazodone is initiated or stopped.
众所周知,华法林存在许多药物相互作用。然而,关于曲唑酮与华法林之间的相互作用,几乎没有数据可供临床医生参考。
在一项回顾性病历审查中,根据未由其他因素解释的凝血酶原时间(PT)和国际标准化比值(INR)变化,确定了3例疑似曲唑酮与华法林相互作用的具有临床意义的病例。在每例病例中,开始或停用曲唑酮后INR变化≥1.0。开始使用曲唑酮的患者,随后PT和INR降低;相反,停止曲唑酮治疗的患者PT和INR升高。尽管没有患者因PT和INR的显著变化而出现不良反应,但在开始和停用曲唑酮时,华法林剂量必须相应调整。
这些病例表明曲唑酮与华法林之间存在潜在的具有临床意义的相互作用。相互作用的起效时间不一;其背后的机制尚不清楚,但可能涉及底物或蛋白质结合竞争。
由于难以达到治疗性PT和INR,强烈不建议正在接受华法林治疗的患者按需使用曲唑酮助眠。在了解更多情况之前,应告知患者和临床医生这种潜在的相互作用,并在开始或停止使用曲唑酮时监测抗凝效果的变化。